Giovanni Di Bonaventura

List of Publications by Year
in descending order

98 papers	5,397 citations	136885 32 h-index	85498 71 g-index
100 all docs	100 docs citations	100 times ranked	7179 citing authors

#	Article	IF	Citations
1	Quantification of biofilm in microtiter plates: overview of testing conditions and practical recommendations for assessment of biofilm production by staphylococci. Apmis, 2007, 115, 891-899.	0.9	1,407
2	Critical review on biofilm methods. Critical Reviews in Microbiology, 2017, 43, 313-351.	2.7	693
3	Influence of temperature on biofilm formation by Listeria monocytogenes on various food-contact surfaces: relationship with motility and cell surface hydrophobicity. Journal of Applied Microbiology, 2008, 104, 1552-1561.	1.4	359
4	Biofilm Formation by the Emerging Fungal Pathogen Trichosporon asahii : Development, Architecture, and Antifungal Resistance. Antimicrobial Agents and Chemotherapy, 2006, 50, 3269-3276.	1.4	198
5	Factors associated with adherence to and biofilm formation on polystyrene byStenotrophomonas maltophilia: the role of cell surface hydrophobicity and motility. FEMS Microbiology Letters, 2008, 287, 41-47.	0.7	167
6	Biofilm Formation by Stenotrophomonas maltophilia : Modulation by Quinolones, Trimethoprim-Sulfamethoxazole, and Ceftazidime. Antimicrobial Agents and Chemotherapy, 2004, 48, 151-160.	1.4	148
7	Fluids and Microbial Penetration in the Internal Part of Cement-Retained Versus Screw-Retained Implant-Abutment Connections. Journal of Periodontology, 2001, 72, 1146-1150.	1.7	110
8	Phenotypic and genotypic characterization of Stenotrophomonas maltophiliaisolates from patients with cystic fibrosis: Genome diversity, biofilm formation, and virulence. BMC Microbiology, 2011, 11, 159.	1.3	108
9	Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients. BMC Microbiology, 2010, 10, 102.	1.3	106
10	Antibacterial and anti-biofilm effects of cathelicidin peptides against pathogens isolated from cystic fibrosis patients. Peptides, 2011, 32, 1807-1814.	1.2	105
11	Comparative evaluation of the Vitek-2 Compact and Phoenix systems for rapid identification and antibiotic susceptibility testing directly from blood cultures of Gram-negative and Gram-positive isolates. Diagnostic Microbiology and Infectious Disease, 2012, 72, 20-31.	0.8	90
12	Evolution of Stenotrophomonas maltophilia in Cystic Fibrosis Lung over Chronic Infection: A Genomic and Phenotypic Population Study. Frontiers in Microbiology, 2017, 8, 1590.	1.5	85
13	Cooperative pathogenicity in cystic fibrosis: Stenotrophomonas maltophilia modulates Pseudomonas aeruginosa virulence in mixed biofilm. Frontiers in Microbiology, 2015, 6, 951.	1.5	82
14	Potential novel therapeutic strategies in cystic fibrosis: antimicrobial and anti-biofilm activity of natural and designed Î±-helical peptides against Staphylococcus aureus, Pseudomonas aeruginosa, and Stenotrophomonas maltophilia. BMC Microbiology, 2012, 12, 145.	1.3	79
15	Determination of ciprofloxacin and levofloxacin in human sputum collected from cystic fibrosis patients using microextraction by packed sorbent-high performance liquid chromatography photodiode array detector. Journal of Chromatography A, 2015, 1419, 58-66.	1.8	71
16	Editorial: A Multidisciplinary Look at Stenotrophomonas maltophilia: An Emerging Multi-Drug-Resistant Global Opportunistic Pathogen. Frontiers in Microbiology, 2017, 8, 1511.	1.5	58
17	Stenotrophomonas maltophilia Phenotypic and Genotypic Diversity during a 10-year Colonization in the Lungs of a Cystic Fibrosis Patient. Frontiers in Microbiology, 2016, 7, 1551.	1.5	55
18	Effect of environmental factors on biofilm formation by clinicalStenotrophomonas maltophilia isolates. Folia Microbiologica, 2007, 52, 86-90.	1.1	51

#	Article	IF	Citations
19	Multidrug-Resistant Escherichia fergusonii : a Case of Acute Cystitis. Journal of Clinical Microbiology, 2008, 46, 1551-1552.	1.8	50
20	In Vitro Pharmacodynamic Characteristics of Amphotericin B, Caspofungin, Fluconazole, and Voriconazole against Bloodstream Isolates of Infrequent Candida Species from Patients with Hematologic Malignancies. Antimicrobial Agents and Chemotherapy, 2004, 48, 4453-4456.	1.4	49
21	Antimicrobial and antibiofilm activity of secondary metabolites of lichens against methicillin-resistant Staphylococcus aureus strains from cystic fibrosis patients. Future Microbiology, 2013, 8, 281-292.	1.0	49
22	Role of Excessive Inflammatory Response to Stenotrophomonas maltophilia Lung Infection in DBA/2 Mice and Implications for Cystic Fibrosis. Infection and Immunity, 2010, 78, 2466-2476.	1.0	48
23	Electrochemically Synthesized Silver Nanoparticles Are Active Against Planktonic and Biofilm Cells of Pseudomonas aeruginosa and Other Cystic Fibrosis-Associated Bacterial Pathogens. Frontiers in Microbiology, 2018, 9, 1349.	1.5	48
24	Haemophilus influenzae in children with cystic fibrosis: Antimicrobial susceptibility, molecular epidemiology, distribution of adhesins and biofilm formation. International Journal of Medical Microbiology, 2012, 302, 45-52.	1.5	47
25	An overview of various typing methods for clinical epidemiology of the emerging pathogen Stenotrophomonas maltophilia. Diagnostic Microbiology and Infectious Disease, 2015, 81, 219-226.	0.8	47
26	New insights in Staphylococcus pseudintermedius pathogenicity: antibiotic-resistant biofilm formation by a human wound-associated strain. BMC Microbiology, 2015, 15, 109.	1.3	47
27	Methicillin-Resistant Staphylococcus pseudintermedius Infection in a Bone Marrow Transplant Recipient. Journal of Clinical Microbiology, 2013, 51, 1636-1638.	1.8	46
28	Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. Alimentary Pharmacology and Therapeutics, 2003, 18, 821-827.	1.9	39
29	Subinhibitory concentrations of moxifloxacin decrease adhesion and biofilm formation of Stenotrophomonas maltophilia from cystic fibrosis. Journal of Medical Microbiology, 2010, 59, 76-81.	0.7	37
30	Tuberculosis-like pneumonias by the aerobic actinomycetes Rhodococcus, Tsukamurella and Gordonia. Microbes and Infection, 2012, 14, 401-410.	1.0	37
31	An Overview on Streptococcus bovis/Streptococcus equinus Complex Isolates: Identification to the Species/Subspecies Level and Antibiotic Resistance. International Journal of Molecular Sciences, 2019, 20, 480.	1.8	37
32	Microbiological Laboratory Diagnosis of Human Brucellosis: An Overview. Pathogens, 2021, 10, 1623.	1.2	37
33	In vitro and in vivo evaluation of BMAP-derived peptides for the treatment of cystic fibrosis-related pulmonary infections. Amino Acids, 2016, 48, 2253-2260.	1.2	35
34	Clonal Diversity, Biofilm Formation, and Antimicrobial Resistance among Stenotrophomonas maltophilia Strains from Cystic Fibrosis and Non-Cystic Fibrosis Patients. Antibiotics, 2020, 9, 15.	1.5	35
35	Gram-Negative Bacteria Holding Together in a Biofilm: The Acinetobacter baumannii Way. Microorganisms, 2021, 9, 1353.	1.6	30
36	In vitro activity of colistin against biofilm by Pseudomonas aeruginosa is significantly improved under â€œcystic fibrosisâ€“likeâ€•physicochemical conditions. Diagnostic Microbiology and Infectious Disease, 2015, 82, 318-325.	0.8	27

#	Article	IF	Citations
37	Do Tonsils Represent an Extragastric Reservoir for Helicobacter pylori infection. Journal of Infection, 2001, 42, 221-222.	1.7	26
38	D-BMAP18 Antimicrobial Peptide Is Active In vitro, Resists to Pulmonary Proteases but Loses Its Activity in a Murine Model of Pseudomonas aeruginosa Lung Infection. Frontiers in Chemistry, 2017, 5, 40.	1.8	25
39	An antimicrobial bicyclic peptide from chemical space against multidrug resistant Gram-negative bacteria. Chemical Communications, 2018, 54, 5130-5133.	2.2	25
40	Phylogenetic relationships, biofilm formation, motility, antibiotic resistance and extended virulence genotypes among Escherichia coli strains from women with community-onset primitive acute pyelonephritis. PLoS ONE, 2018, 13, e0196260.	1.1	25
41	Evaluation of antibacterial and antibiofilm mechanisms by usnic acid against methicillin-resistant Staphylococcus aureus. Future Microbiology, 2016, 11, 1315-1338.	1.0	23
42	Peptide dendrimers as “lead compounds” for the treatment of chronic lung infections by Pseudomonas aeruginosa in cystic fibrosis patients: in vitro and in vivo studies. Infection and Drug Resistance, 2018, Volume 11, 1767-1782.	1.1	23
43	Identification of CTX-M-15 and CTX-M-27 in Antibiotic-Resistant Gram-Negative Bacteria Isolated from Three Rivers Running in Central Italy. Microbial Drug Resistance, 2019, 25, 1041-1049.	0.9	23
44	Femoral Prosthesis Infection byRhodotorula mucilaginosa. Journal of Clinical Microbiology, 2008, 46, 3544-3545.	1.8	22
45	Infection of recurrent calcaneal ulcer caused by a biofilm-producer Myroides odoratimimus strain. Folia Microbiologica, 2018, 63, 203-207.	1.1	22
46	Ambient air pollution and respiratory bacterial infections, a troubling association: epidemiology, underlying mechanisms, and future challenges. Critical Reviews in Microbiology, 2020, 46, 600-630.	2.7	22
47	Two Cases of Vaginitis Caused by Itraconazole-Resistant Saccharomyces cerevisiae and a Review of Recently Published Studies. Mycopathologia, 2008, 166, 47-50.	1.3	19
48	Pan-azole-Resistant Candida guilliermondii from a Leukemia Patientâ€™s Silent Funguria. Mycopathologia, 2010, 169, 457-459.	1.3	19
49	Î²-Lactam Failure in Treatment of Two Group G Streptococcus dysgalactiae subsp. equisimilis Pharyngitis Patients. Journal of Clinical Microbiology, 2008, 46, 814-816.	1.8	18
50	Colonic adenoma-associated Escherichia coli express specific phenotypes. Microbes and Infection, 2019, 21, 305-312.	1.0	18
51	A novel highly charged exopolysaccharide produced by two strains of Stenotrophomonas maltophilia recovered from patients with cystic fibrosis. Carbohydrate Research, 2011, 346, 1916-1923.	1.1	17
52	Biofilm Formation among Stenotrophomonas maltophilia Isolates Has Clinical Relevance: The ANSELM Prospective Multicenter Study. Microorganisms, 2021, 9, 49.	1.6	16
53	In Vitro Activity of Clarithromycin against Intracellular Helicobacter pylori. Antimicrobial Agents and Chemotherapy, 2001, 45, 1568-1571.	1.4	15
54	Comparison of Etest, agar dilution, broth microdilution and disk diffusion methods for testing in vitro activity of levofloxacin against Staphylococcus spp. isolated from neutropenic cancer patients. International Journal of Antimicrobial Agents, 2002, 19, 147-154.	1.1	15

#	Article	IF	Citations
55	Olive PÃ¢tÃ© by Multi-Phase Decanter as Potential Source of Bioactive Compounds of Both Nutraceutical and Anticancer Effects. Molecules, 2020, 25, 5967.	1.7	15
56	Bacterial Contamination of Platelets and Septic Transfusions: Review of the Literature and Discussion on Recent Patents About Biofilm Treatment. Recent Patents on Anti-infective Drug Discovery, 2010, 5, 168-176.	0.5	14
57	Corynebacterium glucuronolyticum causing genitourinary tract infection: Case report and review of the literature. IDCases, 2015, 2, 56-58.	0.4	14
58	Identification, antimicrobial resistance and molecular characterization of the human emerging pathogen Streptococcus gallolyticus subsp. pasteurianus. Diagnostic Microbiology and Infectious Disease, 2016, 86, 329-335.	0.8	14
59	Evaluation of in vitro activity of ceftolozane-tazobactam compared to other antimicrobial agents against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Diagnostic Microbiology and Infectious Disease, 2019, 94, 297-303.	0.8	14
60	Evaluation of the E Test for Antimicrobial Susceptibility Testing of Pseudomonas aeruginosa Isolates from Patients with Long-Term Bladder Catheterization. Journal of Clinical Microbiology, 1998, 36, 824-826.	1.8	14
61	First report of an acute purulent maxillary sinusitis caused by Pseudomonas aeruginosa secondary to dental implant placement in an immunocompetent patient. British Dental Journal, 2011, 211, 205-207.	0.3	11
62	Multidrug-resistant Geotrichum capitatum from a haematology ward. Mycoses, 2011, 54, 542-543.	1.8	11
63	Characterization of Streptococcus pneumoniae clones from paediatric patients with cystic fibrosis. Journal of Medical Microbiology, 2014, 63, 1704-1715.	0.7	11
64	Misidentification of ampicillinâ€“sulbactam heteroresistance in Acinetobacter baumannii strains from ICU patients. Journal of Infection, 2009, 58, 316-317.	1.7	10
65	Exposure to extremely low-frequency magnetic field affects biofilm formation by cystic fibrosis pathogens. Future Microbiology, 2014, 9, 1303-1317.	1.0	10
66	Stenotrophomonas maltophilia Virulence and Specific Variations in Trace Elements during Acute Lung Infection: Implications in Cystic Fibrosis. PLoS ONE, 2014, 9, e88769.	1.1	10
67	Bioactive compounds: a goldmine for defining new strategies against pathogenic bacterial biofilms?. Critical Reviews in Microbiology, 2023, 49, 117-149.	2.7	10
68	First report of vaginal infection caused by Enterococcus raffinosus. Journal of Medical Microbiology, 2008, 57, 672-673.	0.7	9
69	Myroides odoratimimus Forms Structurally Complex and Inherently Antibiotic-Resistant Biofilm in a Wound-Like in vitro Model. Frontiers in Microbiology, 2017, 8, 2591.	1.5	9
70	Growth Control of Adherent-Invasive Escherichia coli (AIEC) by the Predator Bacteria Bdellovibrio bacteriovorus: A New Therapeutic Approach for Crohnâ€™s Disease Patients. Microorganisms, 2020, 8, 17.	1.6	9
71	Rapid Detection of Methicillin-Resistant Staphylococcus aureus Directly from Blood for the Diagnosis of Bloodstream Infections: A Mini-Review. Diagnostics, 2020, 10, 830.	1.3	9
72	In Vitro Newly Isolated Environmental Phage Activity against Biofilms Preformed by Pseudomonas aeruginosa from Patients with Cystic Fibrosis. Microorganisms, 2021, 9, 478.	1.6	9

#	Article	IF	Citations
73	Chloramphenicol and rifampin may be the only options against Stenotrophomonas maltophilia. A tale of a colonized bladder device in a patient with myelofibrosis. Infezioni in Medicina, 2010, 18, 193-7.	0.7	8
74	Graft versus host disease-related Hafnia alvei colonization and probable infection. Journal of Medical Microbiology, 2008, 57, 1167-1169.	0.7	7
75	Normal breathing releases SARS-CoV-2 into the air. Journal of Medical Microbiology, 2021, 70, .	0.7	7
76	Meticillin-heteroresistant Staphylococcus pasteuri from an apheresis platelet product. Journal of Medical Microbiology, 2009, 58, 1527-1528.	0.7	6
77	The Anti-Microbial Peptide (Lin-SB056-1)2-K Reduces Pro-Inflammatory Cytokine Release through Interaction with Pseudomonas aeruginosa Lipopolysaccharide. Antibiotics, 2020, 9, 585.	1.5	6
78	Multidrug-Resistant Enterococcus raffinosus From A Decubitus Ulcer: A Case Report. International Journal of Lower Extremity Wounds, 2008, 7, 36-37.	0.6	5
79	Isolation of colistin-resistant Hafnia alvei. Journal of Medical Microbiology, 2009, 58, 278-280.	0.7	5
80	Fatal sepsis by Klebsiella pneumoniae in a patient with systemic lupus erythematosus: the importance of postmortem microbiological examination for the ex post diagnosis of infection. International Journal of Legal Medicine, 2015, 129, 1097-1101.	1.2	5
81	In vitroactivity of levofloxacin against planktonic and biofilmStenotrophomonas maltophilialifestyles under conditions relevant to pulmonary infection in cystic fibrosis, and relationship with SmeDEF multidrug efflux pump expression. FEMS Microbiology Letters, 2016, 363, fnw145.	0.7	5
82	Staphylococcal Taxonomy. , 2018, , 1-10.		5
83	Giving Drugs a Second Chance: Antibacterial and Antibiofilm Effects of Ciclopirox and Ribavirin against Cystic Fibrosis Pseudomonas aeruginosa Strains. International Journal of Molecular Sciences, 2022, 23, 5029.	1.8	5
84	In vitro Viability of External Eye Microbial Flora in Hydroxy-Propyl-Methylcellulose. Ophthalmologica, 1999, 213, 265-268.	1.0	4
85	An unexpected isolate of Hafnia alvei with reduced susceptibility to cefoxitin. Journal of Infection, 2008, 57, 165-166.	1.7	4
86	In Vitro Antimicrobial Susceptibility Testing of Biofilm-Growing Bacteria: Current and Emerging Methods. Advances in Experimental Medicine and Biology, 2021, , 1.	0.8	4
87	Repurposing the Veterinary Antibiotic Apramycin for Antibacterial and Antibiofilm Activity Against Pseudomonas aeruginosa From Cystic Fibrosis Patients. Frontiers in Microbiology, 2021, 12, 801152.	1.5	4
88	VITEK 2 failure in screening Hafnia alvei inducible Î²-lactam resistance. Journal of Hospital Infection, 2008, 69, 396-398.	1.4	3
89	A case of pharyngitis caused by Streptococcus pneumoniae. Journal of Medical Microbiology, 2008, 57, 674-675.	0.7	3
90	Hafnia alvei from the farm to the delivery room. Veterinary Microbiology, 2013, 163, 202-203.	0.8	3

#	Article	IF	Citations
91	Microbial biofilm: a â€œstickyâ€•problem. Microbiologia Medica, 2018, 33, .	0.3	3
92	Stenotrophomonas maltophilia mutant lacking flagella remains virulent in DBA/2N mice but is less efficient in stimulating TNF-Î± expression. FEMS Microbiology Letters, 2018, 365, .	0.7	3
93	Adhesion and biofilm formation by Staphylococcus aureus clinical isolates under conditions relevant to the host: relationship with macrolide resistance and clonal lineages. Journal of Medical Microbiology, 2019, 68, 148-160.	0.7	3
94	Ulcer Infection by ESÎ²L-Producing Proteus mirabilis: A Case Report. International Journal of Lower Extremity Wounds, 2008, 7, 99-101.	0.6	2
95	In Vitro Microbiology Studies on a New Peritoneal Dialysis Connector. Peritoneal Dialysis International, 2012, 32, 552-557.	1.1	2
96	Quick and reliable galactomannan detection in crude minced lung specimens from haematological patients with suspected invasive fungal infection: results from a case series. European Journal of Clinical Microbiology and Infectious Diseases, 2008, 27, 391-394.	1.3	1
97	Risk of misidentification of Enterobacter aerogenes inducible cephalosporinases. Journal of Infection, 2008, 57, 416-418.	1.7	0
98	Corrigendum to â€œLetter to the Editor â€“ An unexpected isolate of Hafnia alvei with reduced susceptibility to cefoxitinâ€•[Journal of Infection 57 (2008) 165â€“166]. Journal of Infection, 2008, 57, 506.	1.7	0